Byterna Raises Pre-Series A for In Vivo circmRNA CAR-T, Cancer Vaccines
2026-07-23
- China-based Byterna has closed a multimillion RMB Pre-Series A round with continued support from existing investor EFung Capital and new strategic participation from Insilico Medicine. Proceeds will accelerate clinical filing for BR101, a first-in-class dual-target circular mRNA (circmRNA) in vivo CAR-T candidate currently in investigator-initiated trials (IIT), fund an AI-driven personalised circmRNA tumour vaccine pipeline, and co-develop an AI-Native R&D engine with Insilico to integrate mRNA design, synthesis, and translational workflows.
- Founded in June 2023, Byterna specialises in next-generation RNA therapeutics combining the translational stability of circmRNA with AI-guided antigen prediction and sequence optimisation. BR101 aims to generate CAR-T cells directly inside the patient without ex vivo manipulation, potentially reducing manufacturing complexity and cost, whilst the vaccine programme targets a closed-loop, patient-specific design-to-synthesis pathway.
Daily News
3SBio's Sunshine Guojian Files First Global IND for IL-23×TL1A BsAb
2026-08-10
Chinagene's Ophthalmic Gene Therapy Enters Priority Review in China
2026-08-10
BeiGene Raises Full-Year Guidance as H1 Revenue Hits RMB 22.22bn
2026-08-07
Takeda Places First OX2R Agonist for Type 1 Narcolepsy in US Market
2026-08-07
Lilly H1 2026: Tirzepatide Reaches USD 27.7bn, Revenue Up 49%
2026-08-06
Latest Report
2026 TOP-25 Drug Targets
Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation